Sale of 16,141 shares at $26.3622 per share.
Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code S
Traded Sep 1, 2026 · Disclosed Sep 3, 2026
Source: SEC Form 4 · 0002050172-26-000032 · filed 2026-09-03 · View filing →
Composed from the Form 4 as filed with the SEC. Share counts, prices and dates are the filing's own; the disclosure lag is counted in business days from the transaction date to the filing date. What is a Form 4?
Cite this card
Desq Long. "Maze Therapeutics, Inc. (MAZE)." Disclosed 2026-09-03. https://desqlong.com/cards/0002050172-26-000032-2 (retrieved 2026-09-26).